TABLE 2.
FICI for auranofin, cannabidivarin, and tolfenamic acid with ceftriaxone against 70 clinical Neisseria gonorrhoeae isolates
| Antimicrobial combination/strain groupa | MICb (mg/L), median (range) |
FICI,c median (range) | Interpretation | |||
|---|---|---|---|---|---|---|
| MICAsingle | MICAcombined | MICBsingle | MICBcombined | |||
| AUR with CRO | ||||||
| CRO-S (n = 49) | 0.5 (0.125 to 1) | 0.5 (0.125 to 1) | 0.06 (0.002 to 0.125) | 0.06 (0.004 to 0.125) | 1.50 (0.75 to 3.00) | Indifference |
| CRO-R (n = 21) | 0.5 (0.25 to 1) | 0.5 (0.25 to 0.5) | 0.25 (0.25 to 1) | 0.25 (0.25 to 1) | 1.50 (1.00 to 3.00) | Indifference |
| All (n = 70) | 0.5 (0.125 to 1) | 0.5 (0.125 to 1) | 0.06 (0.002 to 1) | 0.06 (0.004 to 1) | 1.50 (0.75 to 3.00) | Indifference |
| CAN with CRO | ||||||
| CRO-S (n = 49) | 8 (4 to 16) | 4 (4 to 8) | 0.06 (0.002 to 0.125) | 0.06 (0.004 to 0.125) | 2.00 (0.75 to 3.00) | Indifference |
| CRO-R (n = 21) | 8 (4 to 16) | 8 (4 to 8) | 0.25 (0.25 to 1) | 0.125 (0.03 to 1) | 1.50 (1.00 to 2.50) | Indifference |
| All (n = 70) | 8 (4 to 16) | 8 (4 to 8) | 0.06 (0.002 to 1) | 0.06 (0.004 to 1) | 1.50 (0.75 to 3.00) | Indifference |
| TOL with CRO | ||||||
| CRO-S (n = 49) | 8 (2 to 16) | 8 (4 to 8) | 0.06 (0.002 to 0.125) | 0.03 (0.004 to 0.125) | 2.00 (0.75 to 3.00) | Indifference |
| CRO-R (n = 21) | 8 (2 to 16) | 4 (2 to 16) | 0.25 (0.25 to 1) | 0.25 (0.06 to 1) | 1.50 (0.75 to 2.50) | Indifference |
| All (n = 70) | 8 (2 to 16) | 4 (2 to 16) | 0.06 (0.002 to 1) | 0.06 (0.004 to 1) | 1.50 (0.75 to 3.00) | Indifference |
a
FICI, fractional inhibitory concentration index; CRO, ceftriaxone; AUR, auranofin; CAN, cannabidivarin; TOL, tolfenamic acid; CRO-S, ceftriaxone-susceptible (MIC ≤ 0.125); CRO-R, ceftriaxone-resistant (MIC > 0.125).
b
MICA is AUR, CAN, or TOL; MICB is CRO.
c
FICI were interpreted using the following criteria: FICI < 0.5: synergy; FICI = 0.5–4.0: indifference; FICI > 4.0: antagonism.